Accuray Continues Global Expansion in South Asia and Announces the
First Two CyberKnife® VSI™ Systems in India
SUNNYVALE, California,
Nov. 21, 2012 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY), the premier radiation oncology
company, announced today that Medanta - The Medicity Cancer
Institute, and the Roentgen-BLK Super Speciality Hospital both
recently acquired and started treating patients with the
CyberKnife® VSI™ System the premier solution for full-body
radiosurgery marking the first-in-country CyberKnife VSI Systems in
India.
Cancer incidence is growing in India with 900,000 new cancer cases and
400,000 cancer deaths annually. Cancers account for eight percent
of total deaths in India thus
creating a larger demand for cancer treatments.
By enriching their therapeutic offerings in radiation oncology,
Medanta - The Medicity Cancer Institute and the Roentgen-BLK
Radiation Oncology Center can now provide patients treatment with
the CyberKnife System and expand the patient population that can
now benefit from CyberKnife radiosurgery and stereotactic body
radiation therapy (SBRT) in the region.
"The CyberKnife System is increasingly being used as an
alternative to conventional radiation therapy in situations where
its targeting accuracy allows a shorter and more intense course of
radiation, including radiosurgery for brain tumors. We are pleased
to have introduced this innovative technology at Medanta and look
forward to witnessing the benefits that the System offers,
including real-time tracking with automatic correction of tumors
that move throughout the body. The CyberKnife System comes as a
significant development in cancer therapy for patients as well as
doctors as it offer the most precise treatment option for a wide
range of patients," said Naresh
Trehan, M.D., Chairman and Managing Director of
Medanta - The Medicity.
"We are always refining radiation oncology treatment methods to
deliver the highest-quality patient care possible, while working to
also reduce or eliminate the side effects that accompany radiation
treatment. Using the CyberKnife System allows our radiation
oncologists to provide the most up-to-date technology available to
accurately target tumors, deliver treatments with pinpoint accuracy
and ensure that tumors get the most effective ablative dose while
healthy tissues and critical structures are spared," said
Praneet Kumar, M.D., CEO of
Roentgen-BLK Radiation Oncology Center.
Building upon the foundation of accuracy and precision in
radiosurgery, the CyberKnife System extends these benefits to
fractionated high precision radiation therapy with robotic
intensity-modulated radiotherapy (IMRT) that can be delivered
anywhere in the body, including intracranial, head and neck, spine,
lung, liver and prostate. The enhanced spectrum of treatment
options allows for more customized treatment plans based on
patient-specific situations and conditions, such as patients
requiring re-irradiation of previously treated area, or patients
requiring partial breast irradiation. With more than 700 hundred
peer-reviewed publications and a rapidly increasing number of
treated patients, the growing community of CyberKnife users is
discovering more applications that can be helped by the
technological edge that the CyberKnife System provides.
About Medanta - The Medicity
Medanta – The Medicity is one of India's largest multi-super specialty
institutes located in Gurgaon, a bustling town in the National
Capital Region. Founded by eminent cardiac surgeon, Dr.
Naresh Trehan, the institution has
been envisioned with the aim of bringing to India the highest standards of medical care
along with clinical research, education and training. It brings
together an outstanding pool of doctors, scientists and clinical
researchers to foster collaborative, multidisciplinary
investigation, inspiring new ideas and discoveries; and translating
scientific advances more swiftly into new ways of diagnosing and
treating patients and preventing diseases. Medanta through its
research integrates modern and traditional forms of medicine to
provide accessible and affordable healthcare. For more information
visit www.medanta.org.
About Roentgen-BLK's Cancer Center
The BLK Super Speciality Hospital's Cancer Center ("BLKCC")
is one of the most modern and comprehensive cancer centers in
Northern India. With over 100 beds
dedicated for oncology services, the department is equipped with
ultra-modern equipment and infrastructure. BLK Super-Speciality
hospital is both NABH and NABL accredited, certifying the quality
of standard of care and the processes that have been put in place
for healthcare delivery. For more information, please visit
http://www.blkhospital.com.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation
oncology company that develops, manufactures and sells personalized
innovative treatment solutions that set the standard of care, with
the aim of helping patients live longer, better lives. The
Company's leading edge technologies – the CyberKnife® and
TomoTherapy® Systems – are designed to deliver radiosurgery,
stereotactic body radiation therapy, intensity modulated radiation
therapy, image guided radiation therapy, and adaptive radiation
therapy. To date, 667 systems have been installed in leading
hospitals around the world. For more information, please visit
www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to growth of cancer patients,
clinical applications, clinical results and patient outcomes, and
the Company's leadership position in radiation oncology innovation.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including risks detailed from time to time under the
heading "Risk Factors" in the company's report on Form 10-K filed
on September 10, 2012, as modified in its Form 10-Q filed on
November 8, 2012, and as updated from
time to time in its other SEC filings. Forward-looking statements
speak only as of the date the statements are made and are based on
information available to the Company at the time those statements
are made and/or management's good faith belief as of that time with
respect to future events. The Company assumes no obligation to
update forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly,
investors should not place undue reliance on any forward-looking
statements.